Australia markets closed

Sight Sciences, Inc. (SGHT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.10+0.03 (+0.30%)
At close: 04:00PM EDT
10.10 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.07
Open9.84
Bid0.00 x 1100
Ask0.00 x 800
Day's range9.84 - 10.46
52-week range6.25 - 40.00
Volume207,379
Avg. volume252,582
Market cap480.662M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

    MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

  • GlobeNewswire

    Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

    Tamara Fountain, M.D. Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain has joined Sight Scienc

  • GlobeNewswire

    Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

    Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucomaThese 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population MENLO PARK, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today